GlassScriptPhysician profile
Sally Worst
NPI 1598482127
$3,187.87
in general payments reported to CMS, 2019-2025
22 companies · $876 in 2025
The $876 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $183 · 2023: $758 · 2024: $1,371 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $491.40 | 2023-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $485.45 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $340.66 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $305.36 | 2022-2025 | Watchman Flx, Watchman Access System |
| Esperion Therapeutics, INC. | $243.31 | 2023-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $236.54 | 2022-2025 | |
| Novo Nordisk INC | $194.38 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $174.70 | 2023-2025 | |
| Daiichi Sankyo INC. | $162.39 | 2023-2025 | Injectafer |
| Inspire Medical Systems, INC. | $158.27 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $74.02 | 2022-2025 | Amvuttra, Onpattro |
| Lexicon Pharmaceuticals, INC. | $52.75 | 2023-2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $45.35 | 2023 | Xarelto |
| Abbott Laboratories | $43.20 | 2023-2024 | Cardiomems, Assurity |
| United Therapeutics Corporation | $39.92 | 2023-2024 | Tyvaso, Orenitram |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.06 | 2024-2025 | Verquvo |
| Amgen INC. | $26.85 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.22 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $20.44 | 2025 | |
| Lilly USA, LLC | $19.23 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $13.51 | 2024 | Arcalyst |
| Vivaquant INC, Dba Rhythm Express | $3.86 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Worst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.